These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18366061)

  • 21. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
    Pricl S; Fermeglia M; Ferrone M; Tamborini E
    Mol Cancer Ther; 2005 Aug; 4(8):1167-74. PubMed ID: 16093432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
    Koldehoff M; Kordelas L; Beelen DW; Elmaagacli AH
    Haematologica; 2010 Mar; 95(3):388-97. PubMed ID: 20207846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
    Mian AA; Schüll M; Zhao Z; Oancea C; Hundertmark A; Beissert T; Ottmann OG; Ruthardt M
    Leukemia; 2009 Sep; 23(9):1614-21. PubMed ID: 19369965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overriding imatinib resistance with a novel ABL kinase inhibitor.
    Shah NP; Tran C; Lee FY; Chen P; Norris D; Sawyers CL
    Science; 2004 Jul; 305(5682):399-401. PubMed ID: 15256671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
    Miething C; Mugler C; Grundler R; Hoepfl J; Bai RY; Peschel C; Duyster J
    Leukemia; 2003 Sep; 17(9):1695-9. PubMed ID: 12970766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
    Yamamoto M; Kurosu T; Kakihana K; Mizuchi D; Miura O
    Biochem Biophys Res Commun; 2004 Jul; 319(4):1272-5. PubMed ID: 15194504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
    Corrado C; Raimondo S; Flugy AM; Fontana S; Santoro A; Stassi G; Marfia A; Iovino F; Arlinghaus R; Kohn EC; Leo GD; Alessandro R
    Cancer Lett; 2011 Jan; 300(2):205-14. PubMed ID: 21041018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
    van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
    Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia.
    Ma B; Feng H; Feng C; Liu Y; Zhang H; Wang J; Wang W; He P; Niu F
    Adv Sci (Weinh); 2022 May; 9(13):e2104850. PubMed ID: 35239999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
    Corbin AS; La Rosée P; Stoffregen EP; Druker BJ; Deininger MW
    Blood; 2003 Jun; 101(11):4611-4. PubMed ID: 12576318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.